A gene therapy for inherited blindness using dCas9-VPR–mediated transcriptional activation

) in a rhodopsin-deficient mouse model for retinitis pigmentosa. One year after treatment, this approach yields improved retinal function and attenuated retinal degeneration with no apparent adverse effects. Our study demonstrates that dCas9-VPR-mediated transcriptional activation of functionally equivalent genes has great potential for the treatment of genetic disorders.

A gene therapy for inherited blindness using dCas9-VPR–mediated transcriptional activation | Litlas